Pila Pharma

<p>Today Pila announced that its rights issue was subscribed to 42,99%, corresponding to SEK6.9m, before issuing costs of a maximum of SEK0.8m. The net proceeds of cSEK6.1m are a nice contribution to Pila’s financial position, and the company now stands financed to submit a clinical phase llb-trial application, according to the press release. The company is also preparing to secure additional financing for the phase llb-trial, which we expect to learn more about during 2023.</p>
<p>Our valuation model already considers the financing required for phase llb, the adjustment for today’s outcome thus has a negligible effect on our valuation of Pila Pharma. We reiterate our SEK 6.1 Base case.</p>
